Re-irradiation as salvage treatment in recurrent glioblastoma: a comprehensive literature review to provide practical answers to frequently asked questions

The median overall survival of patients with GBM remains inferior to 15  months and nearly all patients recur eventually: in the long term, follow-up of patients included in the European Organization for Research and Treatment of Cancer (EORTC)/ National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG) trial (Stupp et al.,2005), only 6% were progression-fre e at 3 years (Stupp et al., 2009).

Source: Critical Reviews in Oncology Hematology - March 31, 2018 Category: Cancer & Oncology Authors: Silvia Scoccianti, Giulio Francolini, Giulio Alberto Carta, Daniela Greto, Beatrice Detti, Gabriele Simontacchi, Luca Visani, Muhammed Baki, Linda Poggesi, Pierluigi Bonomo, Monica Mangoni, Isacco Desideri, Stefania Pallotta, Lorenzo Livi Source Type: research